Literature DB >> 27033328

Somatic Comorbidity in Schizophrenia: Some Possible Biological Mechanisms Across the Life Span.

Ingrid Dieset1, Ole A Andreassen2, Unn K Haukvik3.   

Abstract

Schizophrenia is associated with decreased life expectancy (15-25 y) compared to the general population, with comorbid somatic diseases and in particular cardiovascular diseases being a major cause. Life style and medication probably account for much of the increased mortality risk due to somatic diseases in schizophrenia, but the evidence implicating biological pathways potentially affecting both body and brain is increasing. This includes overlapping genes between schizophrenia and somatic diseases, prenatal risk factors such as hypoxia and infections, and increased cardiovascular disease risk in drug-naïve patients at illness onset. Although environmental bias increases throughout the disease course, there are also some studies on chronic schizophrenia and postmortem brain samples that warrant further attention. In the following, we will attempt to move beyond environmental impact and explore some of the shared pathophysiological mechanisms potentially underlying both schizophrenia and somatic diseases.
© The Author 2016. Published by Oxford University Press on behalf of the Maryland Psychiatric Research Center. All rights reserved. For permissions, please email: journals.permissions@oup.com.

Entities:  

Keywords:  cardio vascular; mortality schizophrenia; schizophrenia; somatic comorbidity

Mesh:

Year:  2016        PMID: 27033328      PMCID: PMC5049521          DOI: 10.1093/schbul/sbw028

Source DB:  PubMed          Journal:  Schizophr Bull        ISSN: 0586-7614            Impact factor:   9.306


  32 in total

Review 1.  Nutritional programming of disease: unravelling the mechanism.

Authors:  Simon C Langley-Evans
Journal:  J Anat       Date:  2008-10-14       Impact factor: 2.610

2.  Accelerated brain aging in schizophrenia and beyond: a neuroanatomical marker of psychiatric disorders.

Authors:  Nikolaos Koutsouleris; Christos Davatzikos; Stefan Borgwardt; Christian Gaser; Ronald Bottlender; Thomas Frodl; Peter Falkai; Anita Riecher-Rössler; Hans-Jürgen Möller; Maximilian Reiser; Christos Pantelis; Eva Meisenzahl
Journal:  Schizophr Bull       Date:  2013-10-13       Impact factor: 9.306

3.  Antipsychotic treatment and mortality in schizophrenia.

Authors:  Minna Torniainen; Ellenor Mittendorfer-Rutz; Antti Tanskanen; Charlotte Björkenstam; Jaana Suvisaari; Kristina Alexanderson; Jari Tiihonen
Journal:  Schizophr Bull       Date:  2014-11-24       Impact factor: 9.306

Review 4.  Prenatal programming of mental illness: current understanding of relationship and mechanisms.

Authors:  Deborah R Kim; Tracy L Bale; C Neill Epperson
Journal:  Curr Psychiatry Rep       Date:  2015-02       Impact factor: 5.285

5.  Impaired fasting glucose tolerance in first-episode, drug-naive patients with schizophrenia.

Authors:  Martina C M Ryan; Patrick Collins; Jogin H Thakore
Journal:  Am J Psychiatry       Date:  2003-02       Impact factor: 18.112

6.  Premature Mortality Among Adults With Schizophrenia in the United States.

Authors:  Mark Olfson; Tobias Gerhard; Cecilia Huang; Stephen Crystal; T Scott Stroup
Journal:  JAMA Psychiatry       Date:  2015-12       Impact factor: 21.596

Review 7.  Targeting myocardial remodelling to develop novel therapies for heart failure: a position paper from the Working Group on Myocardial Function of the European Society of Cardiology.

Authors:  Guido Tarone; Jean-Luc Balligand; Johann Bauersachs; Angela Clerk; Leon De Windt; Stephane Heymans; Denise Hilfiker-Kleiner; Emilio Hirsch; Guido Iaccarino; Ralph Knöll; Adelino F Leite-Moreira; André P Lourenço; Manuel Mayr; Thomas Thum; Carlo G Tocchetti
Journal:  Eur J Heart Fail       Date:  2014-03-17       Impact factor: 15.534

8.  Telomere shortening over 6 years is associated with increased subclinical carotid vascular damage and worse cardiovascular prognosis in the general population.

Authors:  A Baragetti; J Palmen; K Garlaschelli; L Grigore; F Pellegatta; E Tragni; A L Catapano; S E Humphries; G D Norata; P J Talmud
Journal:  J Intern Med       Date:  2014-07-19       Impact factor: 8.989

9.  Microvascular abnormality in schizophrenia as shown by retinal imaging.

Authors:  Madeline H Meier; Idan Shalev; Terrie E Moffitt; Shitij Kapur; Richard S E Keefe; Tien Y Wong; Daniel W Belsky; HonaLee Harrington; Sean Hogan; Renate Houts; Avshalom Caspi; Richie Poulton
Journal:  Am J Psychiatry       Date:  2013-12       Impact factor: 18.112

10.  Biological insights from 108 schizophrenia-associated genetic loci.

Authors: 
Journal:  Nature       Date:  2014-07-22       Impact factor: 49.962

View more
  14 in total

1.  Benzodiazepines and risk of pneumonia in schizophrenia: a nationwide case-control study.

Authors:  Sheng-Yun Cheng; Wen-Yin Chen; Hsing-Cheng Liu; Tien-Wei Yang; Chun-Hung Pan; Shu-Yu Yang; Chian-Jue Kuo
Journal:  Psychopharmacology (Berl)       Date:  2018-09-19       Impact factor: 4.530

2.  Physical Comorbidities are Independently Associated with Higher Rates of Psychiatric Readmission in a Chinese Han Population.

Authors:  Chunyu Yang; Xiaomei Zhong; Huarong Zhou; Zhangying Wu; Min Zhang; Yuping Ning
Journal:  Neuropsychiatr Dis Treat       Date:  2020-09-10       Impact factor: 2.570

3.  Resting-state high-frequency heart rate variability is related to respiratory frequency in individuals with severe mental illness but not healthy controls.

Authors:  Daniel S Quintana; Maja Elstad; Tobias Kaufmann; Christine L Brandt; Beathe Haatveit; Marit Haram; Mari Nerhus; Lars T Westlye; Ole A Andreassen
Journal:  Sci Rep       Date:  2016-11-17       Impact factor: 4.379

4.  Effect of GLP-1 receptor agonist treatment on body weight in obese antipsychotic-treated patients with schizophrenia: a randomized, placebo-controlled trial.

Authors:  Pelle L Ishøy; Filip K Knop; Brian V Broberg; Nikolaj Bak; Ulrik B Andersen; Niklas R Jørgensen; Jens J Holst; Birte Y Glenthøj; Bjørn H Ebdrup
Journal:  Diabetes Obes Metab       Date:  2016-11-14       Impact factor: 6.577

5.  A population study of Norwegian psychiatric patients referred for clinical brain scanning.

Authors:  Mona K Beyer; Turi O Dalaker; Ole J Greve; Siv E Pignatiello; Ingrid Agartz
Journal:  BJPsych Open       Date:  2018-05-08

6.  Review of Standard Laboratory Blood Parameters in Patients with Schizophrenia and Bipolar Disorder.

Authors:  Amra Memic-Serdarevic; Lejla Burnazovic-Ristic; Gorana Sulejmanpasic; Amir Tahirovic; Amina Valjevac; Edina Lazovic
Journal:  Med Arch       Date:  2020-10

7.  Effect of Antipsychotic Treatment on Neutrophil-to-Lymphocyte Ratio during Hospitalization for Acute Psychosis in the Course of Schizophrenia-A Cross-Sectional Retrospective Study.

Authors:  Bartosz Dawidowski; Grzegorz Grelecki; Adam Biłgorajski; Piotr Podwalski; Błażej Misiak; Jerzy Samochowiec
Journal:  J Clin Med       Date:  2021-12-31       Impact factor: 4.241

8.  Exploring the Relationship Between Schizophrenia and Cardiovascular Disease: A Genetic Correlation and Multivariable Mendelian Randomization Study.

Authors:  Rada R Veeneman; Jentien M Vermeulen; Abdel Abdellaoui; Eleanor Sanderson; Robyn E Wootton; Rafik Tadros; Connie R Bezzina; Damiaan Denys; Marcus R Munafò; Karin J H Verweij; Jorien L Treur
Journal:  Schizophr Bull       Date:  2022-03-01       Impact factor: 9.306

Review 9.  Therapeutic Drug Monitoring of Second- and Third-Generation Antipsychotic Drugs-Influence of Smoking Behavior and Inflammation on Pharmacokinetics.

Authors:  Nicole Moschny; Gudrun Hefner; Renate Grohmann; Gabriel Eckermann; Hannah B Maier; Johanna Seifert; Johannes Heck; Flverly Francis; Stefan Bleich; Sermin Toto; Catharina Meissner
Journal:  Pharmaceuticals (Basel)       Date:  2021-05-27

10.  Body Fat Parameters, Glucose and Lipid Profiles, and Thyroid Hormone Levels in Schizophrenia Patients with or without Metabolic Syndrome.

Authors:  Elena G Kornetova; Alexander N Kornetov; Irina A Mednova; Olga A Lobacheva; Valeria I Gerasimova; Viktoria V Dubrovskaya; Ivan V Tolmachev; Arkadiy V Semke; Anton J M Loonen; Nikolay A Bokhan; Svetlana A Ivanova
Journal:  Diagnostics (Basel)       Date:  2020-09-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.